Oxurion Stops 2024 Transaction and Continues Negotiations for New Acquisition

On April 25, 2025, Belgian biopharmaceutical company Oxurion announced the termination of negotiations for the acquisition of a majority stake in a French CRO specialized in stem cells, which had begun in July 2024. The financial conditions, notably influenced by the better-than-expected performance of the target, were not satisfactory for all parties.

Oxurion is nevertheless actively pursuing discussions, which began in March 2025, with a view to acquiring a majority stake in another CRO specializing in biometrics and advanced data management for clinical studies. This acquisition is part of the company's diversification strategy, with completion expected by the end of June 2025.

The company reaffirms its commitment to developing projects that benefit its shareholders while informing the market of progress.